Atlas-backed neurology player Arkuda reemerges from the grindstone with a lead progranulin drug approaching the clinic
In the bustling biotech space, a couple years can feel like an eternity — but for an Atlas Venture-backed neurology player with a novel spin on R&D, a few quiet years aren’t the worst thing in the world.
Arkuda Therapeutics closed a $64 million Series B round co-led by Cormorant Asset Management and Pivotal bioVenture Partners with a lead modulator targeting frontotemporal dementia (FTD) edging closer to the clinic, the company said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.